stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) EBITDA
Amylyx Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was −$158.3M, compared with −$323.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$165.9M. Over the past ten years it has ranged from −$323.7M (fiscal 2024) to $30.0M (fiscal 2023); the current reading is higher than 50% of that period. Amylyx Pharmaceuticals, Inc. ranks 76th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$158.3M | — |
| FY2024 | −$323.7M | — |
| FY2023 | $30.0M | — |
| FY2022 | −$202.9M | — |
| FY2021 | −$82.5M | — |
| FY2020 | −$39.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$46.9M | — |
| Mar 2026 | −$44.3M | — |
| Dec 2025 | −$37.6M | — |
| Sep 2025 | −$37.2M | — |
| 18 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | $571.0M |
| PBH Prestige Consumer Healthcare Inc. compare | $330.9M |
| LQDA Liquidia Corporation compare | $170.3M |
| RGC Regencell Bioscience Holdings Limited compare | −$12.5M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
| TRLV Trulieve Cannabis Corp. compare | −$104.9M |
| AMLX Amylyx Pharmaceuticals, Inc. | −$165.9M |
| PRGO Perrigo Company plc compare | −$1.2B |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$3.3B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement